Coya Therapeutics (NASDAQ:COYA) Stock Rating Lowered by Wall Street Zen

Coya Therapeutics (NASDAQ:COYA – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. Roth Capital reissued a “buy” rating and issued a $12.00 price target on shares of Coya Therapeutics in a report on Monday, August 24th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Thursday. Finally, BTIG Research reiterated a “buy” rating and issued a $16.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Check Out Our Latest Research Report on Coya Therapeutics

Coya Therapeutics Stock Performance

Shares of COYA opened at $3.13 on Friday. The stock’s 50-day simple moving average is $4.29 and its 200 day simple moving average is $4.58. The stock has a market capitalization of $73.43 million, a price-to-earnings ratio of -2.25 and a beta of 0.70. Coya Therapeutics has a 52-week low of $2.72 and a 52-week high of $6.62.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.11). The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.11 million. Coya Therapeutics had a negative return on equity of 71.48% and a negative net margin of 643.44%. On average, research analysts forecast that Coya Therapeutics will post -1.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its position in shares of Coya Therapeutics by 29.6% in the third quarter. Marshall Wace LLP now owns 323,849 shares of the company’s stock worth $1,622,000 after purchasing an additional 74,056 shares during the last quarter. Allworth Financial LP raised its stake in Coya Therapeutics by 1,200.0% in the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after purchasing an additional 12,000 shares in the last quarter. AXQ Capital LP bought a new stake in Coya Therapeutics during the second quarter valued at approximately $116,000. Long Corridor Asset Management Ltd bought a new stake in Coya Therapeutics during the second quarter valued at approximately $227,000. Finally, ADAR1 Capital Management LLC bought a new stake in Coya Therapeutics during the first quarter valued at approximately $161,000. 39.75% of the stock is currently owned by institutional investors.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

See Also

Analyst Recommendations for Coya Therapeutics (NASDAQ:COYA)

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.